(1-ethyl-1H-indazol-5-yl)methanamine | 1370514-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (1-ethyl-1H-indazol-5-yl)methanamine
• 英文别名: (1-ethylindazol-5-yl)methanamine
• CAS: 1370514-39-8
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.233
• InChiKey: DKLRSCLTXAOSFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-ethyl-1H-indazol-5-yl)methanamine 在 caesium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.17h， 生成 methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-((1-ethyl-1H-indazol-5-yl)methyl)sulfamoyl)benzoate
  参考文献：
  名称：

  Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist

  摘要：

  A novel series of 2-pyridyl-benzensulfonamide derivatives have been identified as selective and orally active TRPM8 antagonists via high throughput screening (HTS). Exploration of the structure-activity relationships of compound 1 has led to the identification of RQ-00203078 (compound 36) as a highly selective, potent and orally available TRPM8 antagonist.RQ-00203078 demonstrated excellent in vivo activity in a dose dependent manner with an ED50 value of 0.65 mg/kg in the icilin-induced wet-dog shakes model in rats after oral administration and may become an important pharmacological tool for fully assessing the potential therapeutic use of the targets activated by cold stimulation. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.10.074

文献信息

• [EN] SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS<br/>[FR] DÉRIVÉS HÉTÉROBICYCLIQUES D'ACIDE SULFAMOYLBENZOÏQUE EN TANT QU'ANTAGONISTES DE TRPM8
  申请人：RAQUALIA PHARMA INC

  公开号：WO2012042915A1

  公开（公告）日：2012-04-05

  The present invention relates to sulfamoyl benzoic acid heterobicyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.

  本发明涉及式(I)的磺胺基苯甲酸杂双环衍生物或其药学上可接受的盐或前药，以及其制备方法、含有它们的药物组合物以及它们在治疗通过TRPM8受体介导的各种疾病中的用途。
• SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS
  申请人：Kawamura Kiyoshi

  公开号：US20130210858A1

  公开（公告）日：2013-08-15

  The present invention relates to sulfamoyl benzoic acid heterobicyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.

  本发明涉及公式（I）的磺酰苯甲酸异杂环衍生物或其药学上可接受的盐或前药的制备方法，含有它们的制药组合物以及它们在通过TRPM8受体介导的各种疾病治疗中的应用。
• Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists
  申请人：Kawamura Kiyoshi

  公开号：US08829026B2

  公开（公告）日：2014-09-09

  The present invention relates to sulfamoyl benzoic acid heterobicyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPMb8 receptor.

  本发明涉及式(I)的磺酰苯甲酸杂双环衍生物或其药学上可接受的盐或前药的制备方法，含有它们的制药组合物以及它们在治疗通过TRPMb8受体介导的各种疾病中的应用。
• US8829026B2
  申请人：——

  公开号：US8829026B2

  公开（公告）日：2014-09-09
• Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist
  作者：Masashi Ohmi、Yuji Shishido、Tadashi Inoue、Kazuo Ando、Akiyoshi Fujiuchi、Akiko Yamada、Shuzo Watanabe、Kiyoshi Kawamura

  DOI：10.1016/j.bmcl.2014.10.074

  日期：2014.12

  A novel series of 2-pyridyl-benzensulfonamide derivatives have been identified as selective and orally active TRPM8 antagonists via high throughput screening (HTS). Exploration of the structure-activity relationships of compound 1 has led to the identification of RQ-00203078 (compound 36) as a highly selective, potent and orally available TRPM8 antagonist.RQ-00203078 demonstrated excellent in vivo activity in a dose dependent manner with an ED50 value of 0.65 mg/kg in the icilin-induced wet-dog shakes model in rats after oral administration and may become an important pharmacological tool for fully assessing the potential therapeutic use of the targets activated by cold stimulation. (C) 2014 Elsevier Ltd. All rights reserved.